Article thumbnail
Location of Repository

Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer

By Pierre P. Massion, Yong Zou, Hasmet Uner, Porntip Kiatsimkul, Holly J. Wolf, Anna E. Baron, Tim Byers, Steinn Jonsson, Stephen Lam, Fred R. Hirsch, York E. Miller, Wilbur A. Franklin and Marileila Varella-Garcia

Abstract

Lung carcinoma development is accompanied by field changes that may have diagnostic significance. We have previously shown the importance of chromosomal aneusomy in lung cancer progression. Here, we tested whether genomic gains in six specific loci, TP63 on 3q28, EGFR on 7p12, MYC on 8q24, 5p15.2, and centromeric regions for chromosomes 3 (CEP3) and 6 (CEP6), may provide further value in the prediction of lung cancer. Bronchial biopsy specimens were obtained by LIFE bronchoscopy from 70 subjects (27 with prevalent lung cancers and 43 individuals without lung cancer). Twenty six biopsies were read as moderate dysplasia, 21 as severe dysplasia and 23 as carcinoma in situ (CIS). Four-micron paraffin sections were submitted to a 4-target FISH assay (LAVysion, Abbott Molecular) and reprobed for TP63 and CEP 3 sequences. Spot counts were obtained in 30–50 nuclei per specimen for each probe. Increased gene copy number in 4 of the 6 probes was associated with increased risk of being diagnosed with lung cancer both in unadjusted analyses (odds ratio = 11, p<0.05) and adjusted for histology grade (odds ratio = 17, p<0.05). The most informative 4 probes were TP63, MYC, CEP3 and CEP6. The combination of these 4 probes offered a sensitivity of 82% for lung cancer and a specificity of 58%. These results indicate that specific cytogenetic alterations present in preinvasive lung lesions are closely associated with the diagnosis of lung cancer and may therefore have value in assessing lung cancer risk

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2699220
Provided by: PubMed Central

Suggested articles

Citations

  1. (2006). A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens.
  2. (2002). A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens.
  3. (2000). AIS is an oncogene amplified in squamous cell carcinoma.
  4. (2007). Analyzing Receiver Operating Characteristic Curves
  5. (2006). Assessment of molecular events in squamous and non-squamous cell lung carcinoma.
  6. (1961). Changes in bronchial epithelum in reation to cigraette smoking and in relation to lung cancer.
  7. (2007). Characterizing the cancer genome in lung adenocarcinoma.
  8. (2007). Chromosomal aberrations and gene expression profiles in non-small cell lung cancer.
  9. (2008). Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.
  10. (2005). Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression.
  11. (2003). Chromosome aberrations in solid tumors.
  12. (2005). Clinical practice. Lung cancer screening.
  13. (1997). Comparative genomic hybridization analysis detects frequent, often high- level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas.
  14. (2007). Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung.
  15. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
  16. (2007). Computed tomography screening and lung cancer outcomes.
  17. (1994). Cytogenetic analysis of 63 non-small cell lung carcinomas: recurrent chromosome alterations amid frequent and widespread genomic upheaval.
  18. (2008). DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.
  19. (2009). EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
  20. (1993). Expression of cmyc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers.
  21. (2008). Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
  22. (2002). Focus on lung cancer.
  23. (2001). Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy.
  24. (2008). Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer.
  25. (1990). Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am Rev Respir Dis 142:
  26. (2004). Genetic alteration and gene expression modulation during cancer progression.
  27. (2007). Genetics of preneoplasia: lessons from lung cancer.
  28. (2005). Genome-wide screening of genomic alterations and their clinicopathologic implications in nonsmall cell lung cancers.
  29. (2002). Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
  30. (2006). High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.
  31. (2005). Highresolution genomic profiles of human lung cancer.
  32. (2005). Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
  33. (1986). Human small-cell lung cancers show amplification and expression of the N-myc gene.
  34. (2001). Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
  35. (2002). Molecular Cytogenetic Explorations of Human Genome. In:
  36. (2003). Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy.
  37. (2008). Molecular predictive factors for progression of high-grade preinvasive bronchial lesions.
  38. (2005). Multitarget FISH analysis in the diagnosis of lung cancer.
  39. (2004). Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?
  40. (2004). Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer.
  41. (2005). Novel strategies for the early detection and prevention of lung cancer.
  42. (2007). Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.
  43. (1996). Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography.
  44. (2005). Proteomic patterns of preinvasive bronchial lesions.
  45. (2002). Screening for lung cancer with low-dose helical computed tomography: antilung cancer association project.
  46. (2002). Screening for lung cancer with low-dose spiral computed tomography.
  47. (1994). Specific association of human telomerase activity with immortal cells and cancer.
  48. (2007). Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer.
  49. (2004). Squamous dysplasia and carcinoma
  50. (2006). Survival of patients with stage I lung cancer detected on CT screening.
  51. (2007). The dynamics of cancer chromosomes and genomes.
  52. (1997). Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping.
  53. Wistuba II (2006) Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.